Category: alexknappblog

2023 Breakthrough Prizes Announced: Deepmind’s Protein Folders Awarded $3 Million

The same AI engine that made computers even better at games like Chess and Go could also boost new drug discoveries.

Prime Movers Lab Raises A $500 Million Early Growth Fund To Invest In Breakthrough Science

The new fund will be focused on startups in energy, manufacturing, agriculture, healthcare, satellites and more.

Pfizer And BioNTech Ask FDA To Authorize Omicron Covid Booster

On Monday, Pfizer and BioNTech announced they have asked the FDA to grant an emergency use authorization for their new version of a Covid-19 vaccine that’s been adapted to be specific to the BA.4/BA.5 versions of the Omicron variant.

InnovationRx: WHO Declares Monkeypox Emergency; Plus: Covid’s Animal Origins

InnovationRx is your weekly digest of healthcare news. Sign up!

Butterfly Network Inks Deal To Provide Portable Ultrasound Devices To Medical University Of South Carolina

The company’s devices will be used in clinical and research settings first before being introduced to the medical school.

Novavax Claims Positive Results From Early Trials Of Combination Covid/Flu Vaccine

The company will be moving into more clinical trials for the vaccine through 2022 and 2023.

Pfizer Signs Deal With UNICEF To Distribute Its Covid Antiviral Drug

The pharmaceutical giant will provide 4 million courses of Paxlovid to 95 low- and middle-income countries.

Covid Year 3 Will Be Better, Experts Agree, Unless Rich Countries Ignore The Pandemic Elsewhere

The worst of the pandemic is behind us, experts told Forbes, in part because the first two years provided valuable tools for the continued fight against both Covid and future disease epidemics.

Pfizer’s Started Clinical Trials For Its Covid Antiviral In Kids

The company’s antiviral pill, Paxlovid, is currently authorized for high-risk patients aged 12 and up. This study will look at kids above age 6.

Moderna Aims To Make Vaccines Against 15 Deadly Diseases—And The Next Pandemic

The company’s new public health initiative aims to work with middle- and low-income countries to combat diseases, while working with scientists worldwide to develop vaccines for the next potentially deadly outbreak.